The collection of microorganisms found on and inside the human body is known as human microbiome. A wide variety of microbes, including bacteria, fungus, viruses, and protozoa, can be found in the human microbiome. The bacteria in our microbiome help govern our immune system, digest our food, protect against disease-causing germs, and produce vitamins such as B and K, which are need for blood coagulation.
The market worth of the human microbiome in 2021 was USD 115.42 billion and will be worth USD 1318.72 billion by 2030. Growing at a 31.08% CAGR during 2021-2030.
Factors including the increasing emphasis on microbiome therapies, the rise in the prevalence of diseases link to a sedentary lifestyle, and the expansion of human microbiome research and development will contribute to the market’s expansion.
The global market for human microbiomes is expanding as people become aware of the benefits of the bacteria found in the microbiome for better food digestion. Immune system control, and defense against other disease-causing bacteria. Human microbiome manufacturers operating worldwide are creating diagnostic and therapeutic goods.
Additional important factors contributing to the growth of this market are the rising incidence of diseases connect to a sedentary lifestyle and the rising geriatric population. Per the International Diabetes Federation, 69 million people in Europe between the ages of 20 and 79 will have diabetes by 2045.
The severe government will partially restrain the human microbiome market. Significant barriers, including a lack of knowledge, technological know-how, and qualify specialists, eventually hinder the expansion of the human microbiome market.
Future profitable potential for the business will be expand by an increase in public-private investment for target research initiatives, a rising elderly population, and rising product innovations and development due to global technological improvements.
The therapeutic segment held the highest market position in 2022. This is mostly due to an increase in R&D spending for the creation of technologies and medications base on the microbiome, which fosters segment expansion.
The diagnostics sector will probably expand the fastest by the application due to the scientific and technological advances in mapping. The human genome and the introduction of omics technology.
The market is segment into probiotics, prebiotics, medical foods, and drugs. In 2022, the drug segment significantly rule the entire market, with the largest share of 36% 2022. Bacteria, fungi, and viruses are all part of the human microbiota. Which refers to the billions of microorganisms that coat human tissues. These microbes’ genes are collectively referre to as the “microbiome.”
A rise in medical treatments base on the human microbiome that are now undergoing clinical trials and increase financing for their development may be the cause of this market segment’s sizeable share.
Based on regional analysis, the Global Human Microbiome Market is divide into Asia Pacific, North America, Europe, and the Rest of the World. Europe and North America dominate the global market for the human microbiome due to their top-notch microbiological and biotechnological research infrastructure. The human microbiome sector has grown in these nations partly due to the rising prevalence of autoimmune illnesses and lifestyle diseases.
The market is growing due to the region’s rising illness burden. For instance, the American Cancer Society predicts that in 2022 there will be around 1,918,030 new cases of cancer in the US. Additionally, according to the Globocan 2020 statistics, there are currently 274,364 new cases of cancer, with an expect 400,564 cases by 2040. Because gut bacteria affect tumor therapy by increasing patients’ responsiveness to immunotherapy and reducing the side effects of chemotherapeutic medicines. The rising incidence of cancer will probably accelerate market growth.
The growing number of research projects and the regulatory authorities support for the investigation are also contributing to the market’s growth in the region. For instance, two Live Biotherapeutics, MRx0005 and MRx0029, which are investigational new medicines (IND) for the treatment of Parkinson’s disease, were approve by the FDA in February 2022 by 4D pharma plc. These approvals will probably cause the market to grow.
- Second Genome
- Osel, Inc.
- Seres Therapeutics
- 4D Pharma
- Synthetic Biologics, Inc.
- Rebiotix, Inc.
- Vedanta Biosciences
- Metabiomics Corp.
- Enterome Biosciences SA
- Microbiome Therapeutics LLC
- Ferring Pharmaceuticals
- Du Pont De Nemours and Co.
The market worth of the human microbiome in 2021 was USD 115.42 billion and will be worth USD 1318.72 billion by 2030. Growing at a 31.08% CAGR during 2021-2030. The growth of Industry-Institute Partnerships, the rise in lifestyle diseases, metagenomics technology advancements. The increasing focus on human Microbiome therapeutics, and next-generation sequencing are the major elements driving. The growth of the global human microbiome market.